DexCom is a medical devices business based in the US. DexCom shares (DXCM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $66.33 – a decrease of 3.49% over the previous week. DexCom employs 10,200 staff and has a trailing 12-month revenue of around $4 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $66.33 |
|---|---|
| 52-week range | $57.52 - $139.24 |
| 50-day moving average | $76.29 |
| 200-day moving average | $78.16 |
| Wall St. target price | $99.12 |
| PE ratio | 48.2887 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $66.11 from 2025-04-21
| 1 week (2025-04-16) | -3.81% |
|---|---|
| 1 month (2025-03-21) | -10.42% |
| 3 months (2025-01-23) | -24.62% |
| 6 months (2024-10-23) | -8.79% |
| 1 year (2024-04-23) | -50.66% |
|---|---|
| 2 years (2023-04-21) | -46.57% |
| 3 years (2022-04-22) | 110.1625 |
| 5 years (2020-04-23) | 80.51 |
Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, DexCom shares trade at around 48x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0536. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $817.7 million.
The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4 billion |
|---|---|
| Operating margin TTM | 16.97% |
| Gross profit TTM | $2.4 billion |
| Return on assets TTM | 5.88% |
| Return on equity TTM | 27.63% |
| Profit margin | 14.29% |
| Book value | $5.38 |
| Market Capitalization | $26.9 billion |
TTM: trailing 12 months
We're not expecting DexCom to pay a dividend over the next 12 months.
DexCom's shares were split on a 4:1 basis on 12 June 2022 . So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your DexCom shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for DexCom shares which in turn could have impacted DexCom's share price.
Over the last 12 months, DexCom's shares have ranged in value from as little as $57.52 up to $139.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 1.504. This would suggest that DexCom's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.